H. pylori Eradication Therapy in Pregnancy
H. pylori eradication therapy is generally NOT recommended during pregnancy except in severe hyperemesis gravidarum cases, and when treatment is necessary, amoxicillin-based regimens avoiding tetracyclines, clarithromycin, and metronidazole should be used.
Treatment Indications
The primary indication for H. pylori treatment during pregnancy is severe hyperemesis gravidarum (HG) that is refractory to standard antiemetic therapy. Recent evidence shows H. pylori is strongly associated with HG (RR 5.57) 1, and eradication may provide symptomatic relief in select cases 2.
Standard H. pylori treatment should be deferred until after delivery in asymptomatic pregnant women or those with mild dyspepsia, as the infection itself does not require urgent treatment during pregnancy.
Safe Medication Choices
Antibiotics to AVOID in Pregnancy:
- Tetracycline - teratogenic, causes tooth discoloration and bone abnormalities
- Clarithromycin - FDA Category C, limited safety data
- Metronidazole - concerns in first trimester
- Levofloxacin/fluoroquinolones - cartilage toxicity risk
- Rifabutin - insufficient pregnancy safety data
Acceptable Antibiotic:
- Amoxicillin - FDA Category B, considered safe throughout pregnancy
Acid Suppression:
- Proton pump inhibitors (PPIs) are generally considered safe in pregnancy 3
- Prefer esomeprazole 40 mg or rabeprazole 40 mg twice daily for optimal acid suppression 4
Recommended Regimen (When Treatment is Necessary)
For severe HG cases requiring H. pylori eradication:
Amoxicillin 1000 mg three times daily + High-dose PPI (esomeprazole or rabeprazole 40 mg twice daily) for 14 days
This dual therapy approach:
- Avoids all contraindicated antibiotics
- Achieved 85% eradication rates in pregnant HG patients 2
- Resulted in significant symptom improvement (78% of patients) 2
- Showed no serious adverse effects and reassuring fetal outcomes 2
Clinical Outcomes Data
In the largest study of pregnant HG patients treated for H. pylori 2:
- Hospitalization duration reduced from 7±2 days to 3±1 days (p<0.01)
- Mean birth weight: 3200±500g (normal)
- Preterm delivery rate: 4.8% (comparable to general population)
- Low birth weight: 3.8% (acceptable)
Critical Caveats
Bismuth quadruple therapy is contraindicated - standard first-line therapy 4 contains tetracycline and should never be used in pregnancy
Treatment timing matters - if possible, defer until second trimester when organogenesis is complete
Multidisciplinary approach for HG - H. pylori treatment is adjunctive; continue standard HG management with antiemetics, hydration, and nutritional support 3
Limited evidence base - current data consists primarily of observational studies 1, and routine screening/treatment is not recommended
Confirm infection before treating - use non-invasive testing (stool antigen or urea breath test) rather than endoscopy when possible
Algorithmic Approach
Step 1: Pregnant patient with severe HG refractory to standard antiemetics (pyridoxine, metoclopramide, ondansetron) 3
Step 2: Test for H. pylori (stool antigen or urea breath test)
Step 3: If positive AND symptoms severe enough to warrant treatment:
- Use amoxicillin 1g TID + high-dose PPI BID × 14 days
- Continue standard HG supportive care
Step 4: If mild symptoms or asymptomatic:
- Defer treatment until postpartum
- Manage HG with standard therapies 3
Step 5: Confirm eradication 4+ weeks after completing therapy (stool antigen or urea breath test)
The evidence does not support routine H. pylori screening in all pregnant women 1, and treatment should be reserved for cases where severe HG symptoms justify the intervention.